Selecta Biosciences (SELB) Upgraded to Buy at BidaskClub

BidaskClub upgraded shares of Selecta Biosciences (NASDAQ:SELB) from a hold rating to a buy rating in a research report report published on Thursday morning.

SELB has been the topic of several other research reports. Mizuho restated a buy rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Wednesday, April 11th. Canaccord Genuity restated a buy rating and issued a $40.00 target price on shares of Selecta Biosciences in a report on Thursday, June 28th. ValuEngine upgraded shares of Selecta Biosciences from a sell rating to a hold rating in a report on Saturday, June 2nd. Zacks Investment Research upgraded shares of Selecta Biosciences from a sell rating to a hold rating in a report on Tuesday, May 15th. Finally, Janney Montgomery Scott initiated coverage on Selecta Biosciences in a research note on Wednesday, June 27th. They issued a buy rating and a $33.00 price target for the company. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $28.25.

Shares of Selecta Biosciences stock traded up $0.27 on Thursday, hitting $13.76. The stock had a trading volume of 69,922 shares, compared to its average volume of 102,106. The company has a debt-to-equity ratio of 0.87, a quick ratio of 7.20 and a current ratio of 4.96. Selecta Biosciences has a one year low of $7.95 and a one year high of $24.02. The stock has a market capitalization of $302.13 million, a price-to-earnings ratio of -4.30 and a beta of -3.67.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Selecta Biosciences had a negative return on equity of 150.84% and a negative net margin of 31,556.04%. equities research analysts forecast that Selecta Biosciences will post -3.13 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers lifted its stake in Selecta Biosciences by 43.7% in the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after acquiring an additional 5,103 shares during the period. Alps Advisors Inc. lifted its stake in Selecta Biosciences by 21.0% in the first quarter. Alps Advisors Inc. now owns 29,958 shares of the company’s stock worth $305,000 after acquiring an additional 5,207 shares during the period. Two Sigma Investments LP lifted its stake in Selecta Biosciences by 14.9% in the fourth quarter. Two Sigma Investments LP now owns 59,869 shares of the company’s stock worth $587,000 after acquiring an additional 7,773 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Selecta Biosciences by 37.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after acquiring an additional 9,100 shares during the period. Finally, BlackRock Inc. lifted its stake in Selecta Biosciences by 1.6% in the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock worth $6,420,000 after acquiring an additional 9,749 shares during the period. 45.88% of the stock is owned by institutional investors.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

See Also: Understanding Analyst Recommendations

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply